Octagon Capital Advisors as of June 30, 2025
Portfolio Holdings for Octagon Capital Advisors
Octagon Capital Advisors holds 30 positions in its portfolio as reported in the June 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Dianthus Therapeutics (DNTH) | 9.6 | $44M | 2.3M | 18.63 | |
| Arrivent Biopharma (AVBP) | 9.3 | $42M | 1.9M | 21.77 | |
| Verona Pharma Sponsored Ads (VRNA) | 7.0 | $32M | 337k | 94.58 | |
| Taysha Gene Therapies Com Shs (TSHA) | 6.4 | $29M | 13M | 2.31 | |
| Silverback Therapeutics (SPRY) | 5.2 | $24M | 1.4M | 17.45 | |
| Gossamer Bio (GOSS) | 5.0 | $23M | 18M | 1.23 | |
| Ocular Therapeutix (OCUL) | 4.9 | $23M | 2.4M | 9.28 | |
| Merus N V (MRUS) | 4.5 | $21M | 389k | 52.60 | |
| Trevi Therapeutics (TRVI) | 4.4 | $20M | 3.7M | 5.47 | |
| Cogent Biosciences (COGT) | 4.4 | $20M | 2.8M | 7.18 | |
| Atyr Pharma Com New (ATYR) | 4.3 | $19M | 3.8M | 5.07 | |
| Apellis Pharmaceuticals (APLS) | 3.4 | $16M | 904k | 17.31 | |
| Nuvation Bio Com Cl A (NUVB) | 3.3 | $15M | 7.7M | 1.95 | |
| Tourmaline Bio (TRML) | 3.2 | $15M | 905k | 15.99 | |
| Kalvista Pharmaceuticals (KALV) | 3.2 | $14M | 1.3M | 11.30 | |
| Mind Medicine Mindmed Com New (MNMD) | 3.0 | $14M | 2.1M | 6.49 | |
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 3.0 | $14M | 1.0M | 13.14 | |
| Pharvaris N V (PHVS) | 2.6 | $12M | 673k | 17.60 | |
| Kymera Therapeutics (KYMR) | 2.5 | $12M | 266k | 43.64 | |
| Abivax Sa Sponsored Ads (ABVX) | 2.1 | $9.7M | 1.3M | 7.65 | |
| Dbv Technologies S A Sponsored Ads (DBVT) | 2.0 | $9.3M | 1.0M | 9.15 | |
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 1.7 | $7.7M | 1.1M | 6.90 | |
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 1.5 | $7.0M | 148k | 47.20 | |
| Unicycive Therapeutics Com New (UNCY) | 1.0 | $4.8M | 1.0M | 4.77 | |
| Neurogene (NGNE) | 1.0 | $4.5M | 303k | 14.95 | |
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 0.6 | $2.7M | 250k | 10.65 | |
| Maze Therapeatics (MAZE) | 0.5 | $2.2M | 178k | 12.27 | |
| Kalaris Therapeutics (KLRS) | 0.2 | $961k | 360k | 2.67 | |
| Erasca (ERAS) | 0.2 | $889k | 700k | 1.27 | |
| Nuvation Bio *w Exp 02/10/202 (NUVB.WS) | 0.1 | $301k | 154k | 1.95 |
